Although the small cohort size of 20 patients and variations in clinical follow-up periods certainly narrow the validity of statistical interpretation, high CD31- immunoreactivity could be recognized as a significantly worse outcome parameter in osteosarcoma patients (p = 0,031). The gene discussed is PECAM1; the disease is osteosarcoma.